Lv1
82 积分 2024-06-13 加入
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial
4天前
已完结
NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025
18天前
已完结
Autoimmune effector mechanisms associated with a defective immunosuppressive axis in immune thrombocytopenia (ITP)
18天前
已完结
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18–65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network
1个月前
已完结
Experience of using venetoclax in relapsed T- cell lymphoma
2个月前
已完结
Venetoclax combination with Cladribine, idarubicin, Cytarabine for relapsed T-Cell acute lymphoblastic leukemia/lymphoblastic lymphoma treatment: A case report and literature review
2个月前
已关闭
Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study
2个月前
已完结
Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients
2个月前
已完结
Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma
2个月前
已完结
The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide
3个月前
已完结
皖公网安备34019202002308
